ReviewCurrent problems in pediatric and adolescent health care2018
Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review.
Review in Current problems in pediatric and adolescent health care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03730870 (Assessment of Pharmacogenomics Testing for Improving Pediatric ADHD Psychopharmacological Treatment), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Pharmacogenomics Testing for Improving Pediatric ADHD Psychopharmacological Treatment: A Randomized Controlled Trial
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.Clinical and translational science · 2025Pooled it
- Pooled it
- The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians - A feasibility study.Translational psychiatry · 2026Trial
- Article
- Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations.Clinical pharmacology and therapeutics · 2026Article
- Medication adherence in adolescents: physiological, psychosocial, and clinical perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- Current progress in targeted pharmacotherapy to treat symptoms of major depressive disorder: moving from broad-spectrum treatments to precision psychiatry.CNS spectrums · 2025Review
- Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.Frontiers in pharmacology · 2023Review
- Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review.Neurology and therapy · 2022Review
- Sexual Functioning in Adolescents With Major Depressive Disorder: A Prospective Study.The Journal of clinical psychiatry · 2021Article
- The Utility of Pharmacogenetic-Guided Psychotropic Medication Selection for Pediatric Patients: A Retrospective Study.Pediatric reports · 2021Article
- Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.JAMA network open · 2021Article
- Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years?Journal of child psychology and psychiatry, and allied disciplines · 2021Review
- Article
- Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study.Scientific reports · 2020Article
- Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling.Pediatric research · 2020Review
- Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review.Public health genomics · 2020Review
- Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.Frontiers in pharmacology · 2019Article
- Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges.Pharmacogenomics and personalized medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Significant advances have been made in the application of pharmacogenomic testing for the treatment of patients with psychiatric disorders. Over the past decade, a number of studies have evaluated the utility of pharmacogenomic testing in pediatric patients with psychiatric disorders. The evidence base for pharmacogenomic testing in youth with depressive and anxiety disorders as well as attention/deficit hyperactivity disorder (ADHD) is reviewed in this article. General pharmacogenomic principles are summarized and functional polymorphisms in P450 enzymes (and associated metabolizer phenotypes), the serotonin transporter promoter polymorphisms, serotonin 2A receptor genes (e.g., HT2AR) and catecholamine pathway genes (e.g., COMT) are reviewed. These commonly tested pharmacogenomic markers are discussed with regard to studies of drug levels, efficacy and side effects. The translation of pharmacogenomics to individualized/precision medicine in pediatric patients with ADHD, anxiety and depressive disorders has accelerated; however, its application remains challenging given that there are numerous divergent pathways between medication/medication dose and clinical response and side effects. Nonetheless, by leveraging variations in individual genes that may be relevant to medication metabolism or medication target engagement, pharmacogenomic testing may have a role in predicting treatment response, side effects and medication selection in youth with ADHD, depressive and anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.